Overview

Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS

Status:
NOT_YET_RECRUITING

Trial end date:
2027-04-02

Target enrollment:

Participant gender:

Summary

Reduced intensive 3 + 5 idarubicin and cytarabine chemotherapy plus venetoclax as first-line treatment for adults with acute myeloid leukaemia and high-risk myelodysplastic syndrome

Phase:

PHASE2

Details

Lead Sponsor:

First Affiliated Hospital of Zhejiang University

Treatments:

Cytarabine
Idarubicin